Please assess the completion status of the following clinical trial:

Trial Title: An Open-label Extension Study Evaluating Safety and Tolerability of LCZ696 in Subjects Who Completed PARAGON-HF in Japan.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent must be obtained before any assessment is performed.~* Patients who have completed LCZ696D2301 and are able to be safely enrolled into this study as judged by the investigator.~Exclusion Criteria:~* Patients who discontinued study drug treatment during LCZ696D2301 due to an event or intercurrent illness. Eligibility can be re-considered if the event has resolved and no longer represents a risk to the patient and the patient can safely tolerate the administration of LCZ696 per the investigator's assessment.~* Any medical condition that in the opinion of the investigator is likely to prevent the patient from safely tolerating LCZ696 or complying with the requirements of the study.~* Patients who have experience of angioedema event(s) which occurred and reported by the investigator during LCZ696D2301.~* Pregnant or nursing (lactating) women.~* Women of childbearing potential unless they are using highly effective methods of contraception.~Other protocol-defined inclusion/exclusion may apply.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LCZ696 (Type: EXPERIMENTAL): Starting dose was either 50 mg b.i.d. or 100 mg b.i.d. largely depending on the last dose level taken by the patient at the time of completing PARAGON-HF and patient condition. The dose level was gradually up-titrated with the goal of reaching the target dose of 200 mg b.i.d. as soon as tolerated by the patient

Based on this trial design, predict the completion outcome and termination type (if applicable).